Coronary arterial complications after percutaneous coronary intervention in Behçet’s disease

Toshio Kinoshita¹, Shinichiro Fujimoto¹, Yukio Ishikawa², Hitomi Yuzawa¹, Shunji Fukunaga¹, Mikihito Toda³, Kenji Wagatsuma³, Yoshikiyo Akasaka², Toshiharu Ishii², Takanori Ikeda¹

¹Department of Cardiovascular Medicine, ²Department of Pathology, ³Division of Interventional Cardiology, Toho University Faculty of Medicine, Ohta City, Tokyo, Japan

Abstract: Behçet’s disease is a multisystemic vascular inflammatory disease, but concurrent cardiac diseases, such as acute myocardial infarction, are rare. Several complications may arise after coronary intervention for coronary lesions that interfere with treatment, and the incidence of coronary arterial complications due to invasive therapy remains unclear. Further, the long-term outcomes in patients with Behçet’s disease after stenting for acute myocardial infarction have not been described. The present report describes a 35-year-old Japanese man with Behçet’s disease who developed acute myocardial infarction. A coronary aneurysm developed at the stenting site of the left anterior descending coronary artery, along with stenosis in the left anterior descending segment proximal to the site. Although invasive therapy was considered, medication including immunosuppressants was selected because of the high risk of vascular complications after invasive therapy. The coronary artery disease has remained asymptomatic for 4 years since the patient started medication. This case underscores the importance of considering the incidence of coronary arterial complications and of conservative treatment when possible.

Keywords: Behçet’s disease, myocardial infarction, coronary arterial complications, percutaneous coronary intervention, immunosuppressants

Introduction

Behçet’s disease is a multisystemic inflammatory disease characterized by recurrent oral aphthous ulcers, genital ulcers, uveitis, and skin lesions. Cardiac involvement in Behçet’s disease is rare, and occurs at a rate of 6%–8%, among which myocardial infarction comprises 17.3%. However, treatment for coronary lesions in Behçet’s disease is often difficult, because coronary arterial complications frequently arise after coronary intervention. Thus, the most appropriate approach to treating coronary artery disease with Behçet’s disease is controversial, and the long-term outcomes of coronary lesions in patients with this disease after stenting are unknown. This report describes the long-term outcome of a patient with Behçet’s disease and acute myocardial infarction who developed a coronary aneurysm and stenosis after stenting.

Case report

A 35-year-old Japanese man was admitted to the coronary care unit with chest pain radiating to his left shoulder at rest persisting for one hour. The only coronary risk factor appeared to be smoking. He had no history of food, drug, or metal allergy. Examination on admission revealed weight 55 kg, blood pressure 136/86 mmHg, heart rate 67 beats per minute, and no signs of Behçet’s disease. Electrocardiography revealed normal sinus rhythm, with ST segment elevation in...
leads V1–V5. He was diagnosed with acute myocardial infarction of the anterior wall and immediately underwent primary percutaneous coronary intervention. Coronary angiography demonstrated total occlusion of the proximal left anterior descending coronary artery (LAD, Figure 1A) and no significant lesions in the other arteries. Two stents (Driver®, Medtronic, Santa Rosa, CA; 3.0 × 18 mm, inflation pressure 10 atm) were implanted in the LAD 2 hours after the onset of symptoms (Figure 1B). The peak value for creatine phosphokinase was 1247 IU/L. However, angiographic evidence of possible thrombus was seen in the left main stem coronary artery in spite of an intravenous bolus injection of heparin 5000 IU given just before the procedure. Follow-up coronary angiography was performed after 10 days of heparinization, and angiographic evidence of possible thrombus was no longer visible in the left main stem coronary artery, but a 3 mm aneurysm was seen on the LAD wall where the stent was implanted (Figure 1C). He was discharged on low-dose aspirin, an angiotensin-2 receptor antagonist, a beta-blocker, and a statin. Further follow-up coronary angiography for this aneurysm was scheduled for 2 months later.

One week after discharge, he was readmitted with fever and a skin rash. Physical examination revealed oral aphthous ulceration and dermal pseudofolliculitis, and a skin pathergy test was positive. Hematology results showed the following: C-reactive protein 7.3 mg/dL; white blood cells 13.9 × 10³/µL; and erythrocyte sedimentation rate 58 mm/hour. Gamma globulins, specific antibodies, and antineutrophil cytoplasmic antibodies were negative. He had a history of recurrent oral aphthous ulceration and dermal pseudofolliculitis. He was diagnosed as suffering Behçet’s disease and treated with 30 mg of prednisolone. HLA-B51 was negative. Melena appeared on hospital day 6 and colonoscopy revealed a punched-out ulcer in the terminal ileum, indicating intestinal Behçet’s disease. We added mesalazine 3000 mg and mercaptopurine hydrate 30 mg. Six weeks of this strategy improved his symptoms of fever and melena, and his elevated C-reactive protein, erythrocyte sedimentation rate, and white blood cells. Coronary angiography 2 months after identifying the coronary aneurysm demonstrated that the aneurysm was no longer visible at the LAD stent site, but a new 90% stenosis had appeared in the proximal segment of the LAD (Figure 1D). Although percutaneous coronary intervention and bypass surgery were considered for treatment of this lesion, we opted for medical therapy because he had a high risk of arterial complications after invasive therapy, unstable Behçet’s disease activity, with persistent oral aphthous ulceration but no chest pain. Infliximab 250 mg every 8 weeks was added, and he was discharged on prednisolone 20 mg, mesalazine 3000 mg, and mercaptopurine hydrate 30 mg, along with the cardiovascular medications prescribed previously.

Stress Tc-tetrofosmin scintigraphy confirmed the continued absence of ischemia in his viable myocardium after the optimized medication listed on his discharge prescription. He made good progress with his Behçet’s disease, and his coronary artery disease has remained asymptomatic in the 4 years since starting medication.

### Discussion

Acute myocardial infarction in patients with Behçet’s disease is rare, and the incidence of coronary arterial complications

---

**Table 1** Coronary arterial complications after intervention for ACS in BD (1984–2012)

<table>
<thead>
<tr>
<th>Intervention</th>
<th>No of cases</th>
<th>No of cases with complications (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PCI</td>
<td>12</td>
<td>6 (50)</td>
</tr>
<tr>
<td>POBA</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>Stenting (DES)</td>
<td>5 (1)</td>
<td></td>
</tr>
<tr>
<td>CABG (off pump-CABG)</td>
<td>11 (3)</td>
<td>2 (18)</td>
</tr>
</tbody>
</table>

**Abbreviations:** ACS, acute coronary syndrome; BD, Behçet’s disease; CABG, coronary artery bypass grafting; DES, drug-eluting stent; PCI, percutaneous coronary intervention; POBA, plain old balloon angioplasty.
due to an invasive therapy remains unclear. Here we describe a patient with Behçet’s disease and acute myocardial infarction in whom an aneurysm and proximal stenosis developed in the LAD after stenting. These arterial complications were treated conservatively and the patient was followed up for 4 years.

Although the incidence of coronary arterial involvement in Behçet’s disease after percutaneous coronary intervention and coronary artery bypass grafting is unclear, it seems to be rather frequent. A search of the PubMed (US National Library of Medicine) online database between 1984 and 2012 yielded 40 patients with acute coronary syndrome, including unstable angina pectoris and acute myocardial infarction (see Table 1)\textsuperscript{6–37} (these data originate from previous reports). Of these, 12 and 11 underwent percutaneous coronary intervention and coronary artery bypass grafting, respectively. Coronary arterial complications after percutaneous coronary intervention, including restenosis, reoclusion, coronary aneurysm, and repeated acute myocardial infarction, developed in six (50%) of 12 patients, and two of these six patients underwent coronary artery bypass grafting as a second procedure. Percutaneous coronary intervention was performed in these 12 patients, seven of whom underwent plain old balloon angioplasty alone and five of whom underwent stenting with plain old balloon angioplasty. Complications were observed in two (18%) of 11 patients after coronary artery bypass grafting as the primary treatment, and off-pump coronary artery bypass grafting was performed in three of the 11 patients. These data indicate that invasive treatment for coronary artery disease in patients with Behçet’s disease is associated with a high complication rate. This might be because arterial complications attributable to coronary vasculitis are induced by activated leukocytes via oxidative stress and inflammatory cytokines.\textsuperscript{3}

Our patient also developed an aneurysm in the LAD and high-grade stenosis in the proximal LAD after percutaneous coronary intervention. Given that the patient eventually became free of anginal symptoms and ischemia in the viable myocardium, conservative treatment was appropriate regardless of the severity of the LAD stenosis. However, if angina pectoris becomes unstable and ischemia in viable myocardium is extensive, then either percutaneous coronary intervention or coronary artery bypass grafting is indicated. Sismanoglu et al recommend no-touch techniques for the beating heart with arterial grafts in situ instead of free vein grafts and sequential anastomosis to reduce the number of aortic puncture sites in patients with Behçet’s disease.\textsuperscript{5} Further, postoperative complications in both arteries and veins are significantly decreased in patients who receive immunosuppressants compared with those who do not.\textsuperscript{6}

Our patient was at high risk for complications after invasive treatment of his coronary lesions. However, recent studies have indicated that anti-inflammatory agents, immunosuppressants, and anti-tumor necrosis factor-\(\alpha\) agents are useful for preventing vascular complications arising after invasive procedures.\textsuperscript{5,6,7} Furthermore, the annual incidence of arterial events in patients with Behçet’s disease decreases significantly after immunosuppressive therapy.\textsuperscript{6} Therefore, anti-inflammatory agents and immunosuppressants might have played an important role in achieving a favorable outcome with regard to coronary arterial complications over the long term for our patient. Thus, avoidance of invasive procedures when possible is very important when treating coronary arterial complications in patients with Behçet’s disease. If invasive procedures cannot be avoided, we strongly recommend that intervention be performed with good control of Behçet’s disease activity.

**Acknowledgment**

This report was partly supported by a grant from the Strategic Research Foundation Grant-aided Project for Private schools at Heisei 23th from the Ministry of Education, Culture, Sports, Science and Technology of Japan, 2011–2015.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


Hattori S, Kawana S. Behcet’s syndrome associated with acute myocardial infarction.


